Bevacizumab for recurrent hemangioendothelioma.
Karolin
K
Trautmann
Anne
A
Bethke
Gerhard
G
Ehninger
Gunnar
G
Folprecht
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D005260:Female; D005598:Fractures, Spontaneous / Q000209:etiology / Q000601:surgery; D018323:Hemangioendothelioma, Epithelioid / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D006801:Humans; D007796:Laminectomy; D008159:Lumbar Vertebrae / Q000473:pathology / Q000601:surgery; D008279:Magnetic Resonance Imaging; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D013123:Spinal Fusion; D013125:Spinal Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*; D055815:Young Adult
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab